Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide

Autor: Yukio Sato, Koichi Tokuda, Hajime Kanamori, Ikumi Niitsuma-Sugaya, Issei Seike, Kentaro Takei, Hiroaki Baba, Tetsuji Aoyagi, Kengo Oshima
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Microbiology (medical)
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
viruses
030106 microbiology
Ciclesonide
Gastroenterology
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
Article
Iguratimod
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
RT-PCR
reverse transcription polymerase chain reaction
DMARDs
disease-modifying antirheumatic drugs
Internal medicine
medicine
Pharmacology (medical)
030212 general & internal medicine
SARS
severe acute respiratory syndrome
Viral shedding
skin and connective tissue diseases
COVID-19
coronavirus disease 2019
Coronavirus disease 2019
business.industry
MERS
Middle East respiratory syndrome
Clinical course
medicine.disease
Infectious Diseases
chemistry
Rheumatoid arthritis
CRP
C-reactive protein
business
Antirheumatic drugs
Zdroj: Journal of Infection and Chemotherapy
ISSN: 1341-321X
DOI: 10.1016/j.jiac.2020.06.022
Popis: We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.
Databáze: OpenAIRE
Externí odkaz: